These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 31539535)

  • 41. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
    Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
    Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Role for Estrogen Receptor alpha36 in Cancer Progression.
    Pagano MT; Ortona E; Dupuis ML
    Front Endocrinol (Lausanne); 2020; 11():506. PubMed ID: 32849292
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Increased expression of estrogen receptor α-36 by breast cancer oncogene IKKε promotes growth of ER-negative breast cancer cells.
    Li Q; Sun H; Zou J; Ge C; Yu K; Cao Y; Hong Q
    Cell Physiol Biochem; 2013; 31(6):833-41. PubMed ID: 23816933
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
    Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
    Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
    Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
    APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Low phosphorylation of estrogen receptor alpha (ERalpha) serine 118 and high phosphorylation of ERalpha serine 167 improve survival in ER-positive breast cancer.
    Yamashita H; Nishio M; Toyama T; Sugiura H; Kondo N; Kobayashi S; Fujii Y; Iwase H
    Endocr Relat Cancer; 2008 Sep; 15(3):755-63. PubMed ID: 18550720
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Structure activity relationships and differential interactions and functional activity of various equine estrogens mediated via estrogen receptors (ERs) ERalpha and ERbeta.
    Bhavnani BR; Tam SP; Lu X
    Endocrinology; 2008 Oct; 149(10):4857-70. PubMed ID: 18599548
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Induction of estrogen receptor α-36 expression by bone morphogenetic protein 2 in breast cancer cell lines.
    Wang D; Huang P; Zhu B; Sun L; Huang Q; Wang J
    Mol Med Rep; 2012 Sep; 6(3):591-6. PubMed ID: 22711074
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Estrogen-dependent DLL1-mediated Notch signaling promotes luminal breast cancer.
    Kumar S; Srivastav RK; Wilkes DW; Ross T; Kim S; Kowalski J; Chatla S; Zhang Q; Nayak A; Guha M; Fuchs SY; Thomas C; Chakrabarti R
    Oncogene; 2019 Mar; 38(12):2092-2107. PubMed ID: 30442981
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Estrogen receptor-α signaling in post-natal mammary development and breast cancers.
    Rusidzé M; Adlanmérini M; Chantalat E; Raymond-Letron I; Cayre S; Arnal JF; Deugnier MA; Lenfant F
    Cell Mol Life Sci; 2021 Aug; 78(15):5681-5705. PubMed ID: 34156490
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Estrogen negatively regulates epidermal growth factor (EGF)-mediated signal transducer and activator of transcription 5 signaling in human EGF family receptor-overexpressing breast cancer cells.
    Boerner JL; Gibson MA; Fox EM; Posner ED; Parsons SJ; Silva CM; Shupnik MA
    Mol Endocrinol; 2005 Nov; 19(11):2660-70. PubMed ID: 15976008
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Harmful effect of ERβ on BCRP-mediated drug resistance and cell proliferation in ERα/PR-negative breast cancer.
    Li W; Jia M; Qin X; Hu J; Zhang X; Zhou G
    FEBS J; 2013 Dec; 280(23):6128-40. PubMed ID: 24103091
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cholesterol synthesis inhibitor RO 48-8071 suppresses transcriptional activity of human estrogen and androgen receptor.
    Mafuvadze B; Liang Y; Hyder SM
    Oncol Rep; 2014 Oct; 32(4):1727-33. PubMed ID: 25051231
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Physiologic estrogen receptor alpha signaling in non-tumorigenic human mammary epithelial cells.
    Abukhdeir AM; Blair BG; Brenner K; Karakas B; Konishi H; Lim J; Sahasranaman V; Huang Y; Keen J; Davidson N; Vitolo MI; Bachman KE; Park BH
    Breast Cancer Res Treat; 2006 Sep; 99(1):23-33. PubMed ID: 16541319
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Metalloestrogenic effects of cadmium are absent in long-term estrogen-deprived MCF-7 cells: Evidence for the involvement of constitutively activated estrogen receptor α and very low expression of G protein-coupled estrogen receptor 1.
    Hirao-Suzuki M; Takeda S; Kodama Y; Takiguchi M; Toda A; Ohara M
    Toxicol Lett; 2020 Feb; 319():22-30. PubMed ID: 31689473
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation.
    Martin LA; Farmer I; Johnston SR; Ali S; Dowsett M
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S75-84. PubMed ID: 16113101
    [TBL] [Abstract][Full Text] [Related]  

  • 57. P2Y2 receptor-mediated modulation of estrogen-induced proliferation of breast cancer cells.
    Li HJ; Wang LY; Qu HN; Yu LH; Burnstock G; Ni X; Xu M; Ma B
    Mol Cell Endocrinol; 2011 May; 338(1-2):28-37. PubMed ID: 21356271
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Single-chain estrogen receptors (ERs) reveal that the ERalpha/beta heterodimer emulates functions of the ERalpha dimer in genomic estrogen signaling pathways.
    Li X; Huang J; Yi P; Bambara RA; Hilf R; Muyan M
    Mol Cell Biol; 2004 Sep; 24(17):7681-94. PubMed ID: 15314175
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
    Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
    Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
    [TBL] [Abstract][Full Text] [Related]  

  • 60. ERα-36 regulates progesterone receptor activity in breast cancer.
    Konan HP; Kassem L; Omarjee S; Surmieliova-Garnès A; Jacquemetton J; Cascales E; Rezza A; Trédan O; Treilleux I; Poulard C; Le Romancer M
    Breast Cancer Res; 2020 May; 22(1):50. PubMed ID: 32429997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.